Inside Executives Are Trading These Healthcare Shares Now

Wall St. Watchdog looks at insider trading trends for the 10 largest companies, as measured by market capitalization, in the Healthcare sector.  The insider trading data cover the past six months.

“Insider net transactions” shows the general bullishness of company insiders.  If more insider purchases than sales were made over the six month period, then this value is a positive number; conversely, if more insider sales than purchases were made, this value is a negative number.  The further away from zero this value is, the more bullish (positive) or bearish (negative number) the company’s insiders.  Obviously, a value of zero represents an equal number of sellers and buyers.  Note, also, that the number of shares sold can exceed the number of shares purchased over the six month period, yet the “insider net transactions” number can be positive.  The opposite can be true as well: the number of shares purchased can exceed the number of shares sold, yet the number of sale transactions can be greater than the number of purchase transactions.

Criteria for this stock screen are:

  • Market capitalization greater than $1 billion
  • Insider shares purchased is greater than 0
  • Insider shares sold is greater than 0

Finally, note that the number of shares sold by insiders is shown as a negative number.

  • Johnson + Johnson (NYSE:JNJ): Insiders purchased 480,110 shares in the past 6 months, against insider sales of -379,400 over the past six months. Net transactions were 11 for the six month period. Insiders own 0% of the outstanding shares, of which there are 2,751,400,000. The stock recently traded at $65.92 and its market capitalization is $180,696,200,000. About the company:  Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
  • Pfizer Inc. (NYSE:PFE): Insiders purchased 732,120 shares in the past 6 months, against insider sales of -252,760 over the past six months. Net transactions were 2 for the six month period. Insiders own 0% of the outstanding shares, of which there are 8,036,000,000. The stock recently traded at $19.63 and its market capitalization is $155,099,200,000. About the company: Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Company’s products include prescription pharmaceuticals, non-prescription self-medications, and animal health products such as anti-infective medicines and vaccines.
  • Merck + Co., Inc. (NYSE:MRK): Insiders purchased 416,270 shares in the past 6 months, against insider sales of -149,730 over the past six months. Net transactions were 2 for the six month period. Insiders own 0% of the outstanding shares, of which there are 3,095,000,000. The stock recently traded at $35.79 and its market capitalization is $110,468,900,000. About the company: Merck & Co., Inc. is a global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of human and animal health products. Merck’s products include a treatment for elevated cholesterol, a treatment for male pattern hair loss, a preventive treatment for osteoporosis, a treatment for hypertension, and a treatment for allergic rhinitis.
  • Abbott Laboratories (NYSE:ABT): Insiders purchased 857,530 shares in the past 6 months, against insider sales of -651,400 over the past six months. Net transactions were 3 for the six month period. Insiders own 0% of the outstanding shares, of which there are 1,546,400,000. The stock recently traded at $52.18 and its market capitalization is $81,102,480,000. About the company: Abbott Laboratories discovers, develops, manufactures, and sells a broad and diversified line of health care products and services. The Company’s products include pharmaceuticals, nutritional, diagnostics, and vascular products. Abbott markets its products worldwide through affiliates and distributors.
  • Amgen, Inc. (NASDAQ:AMGN): Insiders purchased 386,680 shares in the past 6 months, against insider sales of -164,160 over the past six months. Net transactions were 14 for the six month period. Insiders own 0% of the outstanding shares, of which there are 960,000,000. The stock recently traded at $54.70 and its market capitalization is $50,856,260,000. About the company: Amgen Inc. discovers, develops, manufactures, and markets human therapeutics based on cellular and molecular biology. The Company focuses its research on secreted protein and small molecule therapeutics, with particular emphasis on neuroscience and cancer. Amgen concentrates on the areas of hematology, cancer, infectious disease, endocrinology, neurobiology, and inflammation.
  • Bristol Myers Squibb Co. (NYSE:BMY): Insiders purchased 2,042,220 shares in the past 6 months, against insider sales of -2,390,620 over the past six months. Net transactions were 0 for the six month period. Insiders own 0% of the outstanding shares, of which there are 1,713,000,000. The stock recently traded at $29.04 and its market capitalization is $49,541,910,000. About the company: Bristol-Myers Squibb Company is a global biopharmaceutical company that discovers, develops, manufactures and sells pharmaceutical and nutritional products. The Company’s products and experimental therapies address cancer, heart disease, HIV/AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection and psychiatric disorders.
  • Eli Lilly + Co. (NYSE:LLY): Insiders purchased 498,550 shares in the past 6 months, against insider sales of -333,620 over the past six months. Net transactions were -2 for the six month period. Insiders own 0% of the outstanding shares, of which there are 1,105,788,000. The stock recently traded at $38.46 and its market capitalization is $44,523,850,000. About the company: Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products for humans and animals. The Company’s products are sold in countries around the world. Eli Lilly’s products include neuroscience products, endocrine products, anti-infectives, cardiovascular agents, oncology products, and animal health products.
  • Medtronic, Inc. (NYSE:MDT): Insiders purchased 459,190 shares in the past 6 months, against insider sales of -0,380 over the past six months. Net transactions were 10 for the six month period. Insiders own 0% of the outstanding shares, of which there are 1,077,400,000. The stock recently traded at $36.34 and its market capitalization is $38,555,000,000. About the company:  Medtronic, Inc. develops therapeutic and diagnostic medical products. The Company’s principal products include those for bradycardia pacing, tachyarrhythmia management, atrial fibrillation management, heart failure management, heart valve replacement, malignant and non-malignant pain, and movement disorders. Medtronic’s products are sold worldwide.
  • Baxter International Inc. (NYSE:BAX): Insiders purchased 32,810 shares in the past 6 months, against insider sales of -15,010 over the past six months. Net transactions were 8 for the six month period. Insiders own 0% of the outstanding shares, of which there are 590,000,000. The stock recently traded at $60.65 and its market capitalization is $34,593,400,000. About the company: Baxter International Inc. develops, manufactures, and markets products and technologies related to hemophilia, immune disorders, infectious diseases, kidney disease, trauma and other chronic and acute medical conditions. The Company’s products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors’ offices, and research laboratories.
  • Gilead Sciences, Inc. (NASDAQ:GILD): Insiders purchased 966,330 shares in the past 6 months, against insider sales of -844,380 over the past six months. Net transactions were 10 for the six month period. Insiders own 1% of the outstanding shares, of which there are 856,060,000. The stock recently traded at $42.16 and its market capitalization is $33,182,210,000. About the company: Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops, and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases. The Company’s primary arees of focus include HIV/AIDS, liver disease and serious cardiovascular and respiratory conditions.

(Note: Selected financial data are sourced from screener.co.  All data are assumed to be accurate.)

Advantage: Check out our interactive stock charts, fundamentals, Twitter stream, and more >>

Improve Your 2011 Financial Health: Join the winning team of stock pickers with Wall St. Cheat Sheet’s acclaimed premium newsletter >>

More from The Cheat Sheet